136 related articles for article (PubMed ID: 7670111)
1. Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas.
Uchida T; Watanabe T; Kinoshita T; Murate T; Saito H; Hotta T
Blood; 1995 Oct; 86(7):2724-31. PubMed ID: 7670111
[TBL] [Abstract][Full Text] [Related]
2. Alterations of CDKN2 (p16) in non-small cell lung cancer.
de Vos S; Miller CW; Takeuchi S; Gombart AF; Cho SK; Koeffler HP
Genes Chromosomes Cancer; 1995 Nov; 14(3):164-70. PubMed ID: 8589032
[TBL] [Abstract][Full Text] [Related]
3. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage.
Nakao M; Yokota S; Kaneko H; Seriu T; Koizumi S; Takaue Y; Fujimoto T; Misawa S
Leukemia; 1996 Feb; 10(2):249-54. PubMed ID: 8637233
[TBL] [Abstract][Full Text] [Related]
4. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies.
Dreyling MH; Bohlander SK; Le Beau MM; Olopade OI
Blood; 1995 Sep; 86(5):1931-8. PubMed ID: 7544647
[TBL] [Abstract][Full Text] [Related]
5. Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas.
Otsuki T; Clark HM; Wellmann A; Jaffe ES; Raffeld M
Cancer Res; 1995 Apr; 55(7):1436-40. PubMed ID: 7882348
[TBL] [Abstract][Full Text] [Related]
6. The CDKN2 gene alterations in various types of adult T-cell leukaemia.
Uchida T; Kinoshita T; Watanabe T; Nagai H; Murate T; Saito H; Hotta T
Br J Haematol; 1996 Sep; 94(4):665-70. PubMed ID: 8826890
[TBL] [Abstract][Full Text] [Related]
7. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
Raffel C; Ueki K; Harsh GR; Louis DN
Neurosurgery; 1995 May; 36(5):971-4; discussion 974-5. PubMed ID: 7791990
[TBL] [Abstract][Full Text] [Related]
8. p16 gene homozygous deletions in acute lymphoblastic leukemia.
Quesnel B; Preudhomme C; Philippe N; Vanrumbeke M; Dervite I; Lai JL; Bauters F; Wattel E; Fenaux P
Blood; 1995 Feb; 85(3):657-63. PubMed ID: 7833469
[TBL] [Abstract][Full Text] [Related]
9. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
Ogawa S; Hangaishi A; Miyawaki S; Hirosawa S; Miura Y; Takeyama K; Kamada N; Ohtake S; Uike N; Shimazaki C
Blood; 1995 Aug; 86(4):1548-56. PubMed ID: 7632963
[TBL] [Abstract][Full Text] [Related]
10. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
[TBL] [Abstract][Full Text] [Related]
11. Deletions and rearrangement of CDKN2 in lymphoid malignancy.
Stranks G; Height SE; Mitchell P; Jadayel D; Yuille MA; De Lord C; Clutterbuck RD; Treleaven JG; Powles RL; Nacheva E
Blood; 1995 Feb; 85(4):893-901. PubMed ID: 7849311
[TBL] [Abstract][Full Text] [Related]
12. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines.
Zhou X; Suzuki H; Shimada Y; Imamura M; Yin J; Jiang HY; Tarmin L; Abraham JM; Meltzer SJ
Genes Chromosomes Cancer; 1995 Aug; 13(4):285-90. PubMed ID: 7547637
[TBL] [Abstract][Full Text] [Related]
13. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
14. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
Schuyer M; van Staveren IL; Klijn JG; vd Burg ME; Stoter G; Henzen-Logmans SC; Foekens JA; Berns EM
Br J Cancer; 1996 Oct; 74(7):1069-73. PubMed ID: 8855976
[TBL] [Abstract][Full Text] [Related]
15. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Fujishita T; Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
[TBL] [Abstract][Full Text] [Related]
16. Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias.
Delmer A; Tang R; Senamaud-Beaufort C; Paterlini P; Brechot C; Zittoun R
Leukemia; 1995 Jul; 9(7):1240-5. PubMed ID: 7630199
[TBL] [Abstract][Full Text] [Related]
17. CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia.
Schröder M; Mathieu U; Dreyling MH; Bohlander SK; Hagemeijer A; Beverloo BH; Olopade OI; Stilgenbauer S; Fischer K; Bentz M
Br J Haematol; 1995 Dec; 91(4):865-70. PubMed ID: 8547131
[TBL] [Abstract][Full Text] [Related]
18. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia.
Hatta Y; Hirama T; Miller CW; Yamada Y; Tomonaga M; Koeffler HP
Blood; 1995 May; 85(10):2699-704. PubMed ID: 7742529
[TBL] [Abstract][Full Text] [Related]
19. LOH and mutation analysis of CDKN2 in primary human ovarian cancers.
Campbell IG; Foulkes WD; Beynon G; Davis M; Englefield P
Int J Cancer; 1995 Oct; 63(2):222-5. PubMed ID: 7591208
[TBL] [Abstract][Full Text] [Related]
20. Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens.
Calvano JE; Rush EB; Tan LK; Rosen PP; Borgen PI; Van Zee KJ
Ann Surg Oncol; 1997; 4(5):416-20. PubMed ID: 9259969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]